Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/08/2022* -- Results Q3 2022 -- -0.85 --
11/08/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 -0.78 -0.80 3.08%
08/03/2022 08:00 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 -0.74 -0.79 5.87%
05/04/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 -0.61 -0.73 16.06%
02/24/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/08/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since -34.67%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.
URL https://www.editasmedicine.com
Investor Relations URL https://ir.editasmedicine.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 08, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
89.34%
-25.97%
30.15%
136.8%
-62.13%
-54.01%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-22.42%
--
--
--
--
--
-39.96%
-11.27%
-83.51%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-70.79%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-52.15%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-41.66%
As of September 26, 2022.

Profile

Edit
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.
URL https://www.editasmedicine.com
Investor Relations URL https://ir.editasmedicine.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 08, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
XDNA 204779.0 USD 4.19%
CDNA.TO 31322.00 USD 3.25%
GNOM 3.994M USD 1.99%
IDNA 2.784M USD 1.64%
KRXCX 94640.00 USD 0.52%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter EDIT Tweets